Fetal Globin Induction—Can It Cure β Thalassemia?
Open Access
- 1 January 2005
- journal article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2005 (1) , 38-44
- https://doi.org/10.1182/asheducation-2005.1.38
Abstract
The β thalassemias are one of a few medical conditions in which reactivation of a gene product that is expressed during fetal life can functionally replace a deficiency of essential proteins expressed at a later developmental stage. The fetal globin genes are present and normally integrated in hematopoietic stem cells, and at least one fetal gene appears accessible for reactivation, particularly in β° thalassemia. However, rapid cellular apoptosis from α globin chain precipitation, and relatively low levels of endogenous erythropoietin (EPO) in some β+ thalassemia patients contribute to the anemia in β thalassemia syndromes.Keywords
This publication has 46 references indexed in Scilit:
- Treatment of β-Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion MoleculesActa Haematologica, 2004
- A signaling mechanism for growth-related expression of fetal hemoglobinBlood, 2004
- Hydroxyurea Therapy in ThalassemiaaAnnals of the New York Academy of Sciences, 1998
- Recombinant Erythropoietin Trial in Children with Transfusion-Dependent Homozygous β-ThalassemiaActa Haematologica, 1997
- Administration of high doses of recombinant human erythropoietin to patients with β‐thalassemia intermedia: a preliminary trialEuropean Journal of Haematology, 1997
- Recombinant human erythropoietin trial in thalassemia intermediaJournal of Tropical Pediatrics, 1996
- Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesisBritish Journal of Haematology, 1995
- Pharmacologic treatment of thalassemia intermedia with hydroxyureaThe Journal of Pediatrics, 1994
- Treatment with Azacitidine of Patients with End-Stage β-ThalassemiaNew England Journal of Medicine, 1993
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982